Back to top
more

Masimo (MASI)

(Delayed Data from NSDQ)

$140.43 USD

140.43
1,106,202

-2.57 (-1.80%)

Updated Sep 19, 2025 04:00 PM ET

After-Market: $140.34 -0.09 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (92 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Masimo Posts Solid Preliminary 2019 Results, Issues Guidance

by Zacks Equity Research

Higher revenues and upbeat 2020 outlook benefit Masimo's (MASI) preliminary full-year 2019 results.

Zacks Equity Research

Masimo's Neonatal RD SET Pulse Oximetry Sensors Get FDA Nod

by Zacks Equity Research

Masimo (MASI) will cater to the whole prenatal patient population, with the recent FDA clearance within the SET pulse oximetry business.

Zacks Equity Research

Here's Why You Should Hold on to Masimo (MASI) Stock Now

by Zacks Equity Research

Masimo (MASI) raises revenue and earnings guidance for 2019.

Zacks Equity Research

Masimo (MASI) Expands Partnership with Texas-Based Drager

by Zacks Equity Research

Masimo (MASI) sees a slew of developments in recent times.

Trina Mukherjee headshot

Digital Health Gaining Momentum: 3 MedTech Stocks in Focus

by Trina Mukherjee

Digital health is committed to changing the face of healthcare as evident from its innovative solutions for the betterment of patients' lives.

Zacks Equity Research

Here's Why You Should Hold on to Masimo (MASI) Stock Now

by Zacks Equity Research

Masimo (MASI) raises 2019 revenue and EPS guidance.

Zacks Equity Research

Masimo (MASI) Earnings Beat Estimates in Q3, View Raised

by Zacks Equity Research

Masimo (MASI) raises its 2019 product revenue guidance.

Zacks Equity Research

Masimo (MASI) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Masimo (MASI) delivered earnings and revenue surprises of 7.04% and 3.69%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Medical Products' Oct 30 Earnings Roster: MCK, MASI & More

by Zacks Equity Research

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have driven the performance of the players in the medical products space this earnings season.

Zacks Equity Research

Masimo (MASI) Reports Next Week: What You Should Expect

by Zacks Equity Research

Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Here's Why You Should Retain HMS Holdings (HMSY) Stock For Now

by Zacks Equity Research

HMS Holdings (HMSY) is gaining traction from growing PI and TPM analytical services as well as robust margins despite intense competition.

Zacks Equity Research

Cerner (CERN) Set to Improve Patient Experience With New Deal

by Zacks Equity Research

The collaboration with GetWellNetwork is likely to allow Cerner (CERN) in enhancing functionality for clients and patients through third-party solutions.

Zacks Equity Research

Here's Why You Should Hold Onto Cerner (CERN) Stock for Now

by Zacks Equity Research

Cerner (CERN) keeps its 2019 revenue guidance intact; expects improvement in bookings.

Zacks Equity Research

NextGen's (NXGN) Population Health Picked by Ohio-Based UH

by Zacks Equity Research

NextGen's (NXGN) EHR services are expected to enhance patient outcomes at UH.

Zacks Equity Research

Fresenius Medical Launches 4008A Dialysis Machine in China

by Zacks Equity Research

Fresenius Medical (FMS) aims to treat ESRD patients in remote locations of China.

Trina Mukherjee headshot

Sleep Apnea Market Gains Momentum: 3 Stocks in Focus

by Trina Mukherjee

Sleep apnea - a significant health issue in the United States - is a booming market, thereby reflecting promising investment prospects.

Zacks Equity Research

Is Masimo (MASI) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (MASI) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Accuray's (ARAY) CyberKnife Delivers Improved Patient Outcome

by Zacks Equity Research

Accuray's (ARAY) CyberKnife delivers stereotactic body radiation therapy in only five sessions.

Zacks Equity Research

Varian's ProBeam Now Available in Multi-Room Configuration

by Zacks Equity Research

Shandong Cancer Hospital in China selects Varian (VAR) to equip its new research center with the ProBeam Proton Therapy system.

Zacks Equity Research

Varian's AI-Driven Ethos Solution to Boost Global Cancer Care

by Zacks Equity Research

Varian (VAR) expects the Ethos launch to boost its Oncology Systems segment.

Zacks Equity Research

Medidata (MDSO) Collaborates With Mapi Research to Boost Rave

by Zacks Equity Research

Medidata's (MDSO) latest collaboration is expected to solve major eCOA implementation struggles in the pharmaceutical industry.

Zacks Equity Research

Ecolab's (ECL) Nalco Water Opens Customer Experience Center

by Zacks Equity Research

Ecolab (ECL) expects Nalco's water technologies to reduce freshwater usage by 20%.

Zacks Equity Research

Masimo (MASI) Boosts O3 Platform With Three New Indices

by Zacks Equity Research

Masimo (MASI) announced the development of three additional indices for O3 Regional Oximetry, thereby improving the O3 platform.

Zacks Equity Research

Here's Why Investors Should Retain Accuray (ARAY) Stock Now

by Zacks Equity Research

Accuray (ARAY) slashes fiscal 2020 revenue guidance owing to tariffs in China.

Zacks Equity Research

Masimo (MASI) Introduces Pathway, Boosts Patient Monitoring

by Zacks Equity Research

Masimo's (MASI) new feature, Pathway, is likely to help clinicians simplify their workflow associated with newborn resuscitation, thereby improving patient monitoring.